Search Results

Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise to develop a growing pipeline of targeted, clinical-stage therapeutics for Parkinson’s and neurodegeneration, announced that Stephen Hahn, M.D. will join its Board of Directors.

Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise to develop a growing pipeline of targeted, clinical-stage therapeutics for Parkinson’s and neurodegeneration, today announced that it has entered into an agreement with an undisclosed partner to acquire rights to a Phase 3-ready drug to treat Parkinson’s.

Blackfynn announced a series of new and expanded partnerships and a key addition to its clinical leadership team.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Blackfynn today announce a new partnership focused on deriving insights from the MJFF-sponsored Parkinson’s Progression Markers Initiative (PPMI) that could lead to discovery of disease biomarkers and new treatments for Parkinson’s disease (PD).

Blackfynn has announced a series of new partnerships, funding, strategic initiatives and team members that extend its position as the leading data platform for neuroscience and neurology.